

Translational Oncology

PUBLICATIONS

- * Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, Gil J, Moreno-Bueno G, Palmero I. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. *Oncogene*. 2016;35(27):3485-94. Article. IF: 7.519; D1
- * Almagro E, González CS, Espinosa E. Prognostic factors of early breast cancer. *Med Clin-Barcelona*. 2016;146(4):167-71. Review. IF: 1.125; Q3
- * Arance AM, Berrocal A, López-Martín JA, de la Cruz-Merino L, Soriano V, Algarra SM, Alonso L, Cerezuela P, la Orden B, Espinosa E. Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience. *Clin Transl Oncol*. 2016;18(11):1147-57. Article. IF: 2.353; Q3
- * Bargiela-Iparraguirre J, Prado-Marchal L, Fernández-Fuente M, Gutiérrez-González A, Moreno-Rubio J, Muñoz-Fernández M, Sereno M, Sánchez-Prieto R, Perona R, Sánchez-Pérez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. *Sci Rep-Uk*. 2016;6:21519. Article. IF: 4.259; Q1
- * Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JEL, García TG, Mancenido FA, Lacalle A, Cardona MF, Mangas M, Visa L, Buxo E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a National Cancer Registry. *J Natl Compr Canc Ne*. 2016;14(11):1379-88. Article. IF: 4.675; Q2
- * Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CSW, Mendiola M, Burgos E, Feliú J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. *Nat Med*. 2016;22(6):685-91. Article. IF: 29.886; D1
- * Espinosa E, Soriano V, Malveyh J, Berrocal A, de Prado PM, Quindos M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puertolas T, Díaz-Beveridge R, de la Cruz-Merino L, Castro RL, López RL, Stevinson K, del Barrio P, Tornamira MV, Guillem V, Martín-Algarra S. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study. *Melanoma Res*. 2016;26(3):278-83. Article. IF: 2.615; Q2
- * Forner A, Reig M, Varela M, Burrel M, Feliú J, Briceno J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. *Med Clin-Barcelona*. 2016;146(11):511.e1-511.e22. Article. IF: 1.125; Q3
- * García-Alfonso P, Feliú J, García-Carbonero R, Grávalos C, Guillén-Ponce C, Sastre J, García-Foncillas J. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? *Clin Transl Oncol*. 2016;18(11):1072-81. Review. IF: 2.353; Q3
- * Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Cajal TRY, Hernández-Agudo E, Soto VH, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusido M, Redondo A, Paz-Ares L,

Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. *J Gynecol Oncol*. 2016;27(1):e7. Article. IF: 3.14; Q1

- * González-Martín A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramenda JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JA, de la Haba J, López R, López-Vivanco G, Martínez-Janez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure A, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MA, Tusquets I, Zamora P, Martín M. Nab-paclitaxel in metastatic breast cancer: Defining the best patient profile. *Curr Cancer Drug Tar*. 2016;16(5):415-28. Article. IF: 2.992; Q3
- * Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliú J. Management of pancreatic cancer in the elderly. *World J Gastroentero*. 2016;22(2):764-75. Article. IF: 3.365; Q2
- * Laimito KR, Gámez-Pozo A, Sepulveda J, Manso L, López-Vacas R, Pascual T, Vara JAF, Ciruelos E. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. *Ecancermedicallscience*. 2016;10:632. Article. IF: Not Indexed
- * Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. *Crit Rev Oncol Hemat*. 2016;105:65-72. Review. IF: 4.971; Q1
- * López-Gómez M, Casado E, Muñoz M, Alcalá S, Moreno-Rubio J, D'Errico G, Jiménez-Gordo AM, Salinas S, Sainz B. Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives. *Crit Rev Oncol Hemat*. 2016;107:54-71. Review. IF: 4,971; Q1.NO
- * Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. *Clin Transl Oncol*. 2016;18(10):1044-50. Article. IF: 2.353; Q3
- * Martín-Broto J, Pousa AL, de las Penas R, del Muro XG, Gutiérrez A, Martínez-Trufero J, Cruz J, Álvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martín JA, Sala A, Meana JA, Ramos R, Martínez-Serra J, López-Guerrero JA, Sevilla I, Balana C, Vaz A, de Juan A, Alemany R, Poveda A. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A Spanish group for research on sarcoma study. *J Clin Oncol*. 2016;34(19):2294-302. Article. IF: 24.008; D1
- * Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, Velasco-Martín JP, Orozco RM, Luengo E, Martín RG, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. *P Natl Acad Sci Usa*. 2016;113(3):E328-37. Article. IF: 9.661; D1
- * Martínez-Jánez N, Chacón I, de Juan A, Cruz-Merino L, del Barco S, Fernández I, García-Tejjido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 therapy beyond second-line for HER2-positive metastatic breast cancer: A short review and recommendations for several clinical scenarios from a Spanish expert panel. *Breast Care*. 2016;11(2):133-8. Article. IF: 1.553; Q3
- * Martín-Richard M, Beveridge RD, Arrazubi V, Alsina M, Guzmán MG, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). *Clin Transl Oncol*. 2016;18(12):1179-86. Article. IF: 2.353; Q3

- * Maurel J, López-Pousa A, Calabuig S, Bague S, del Muro XG, Sanjuan X, Rubio-Casadevall J, Cuatrecasas M, Martínez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Láinez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. *Clin Sarcoma Res.* 2016;6:10. Article. IF: Not Indexed
- * Mendiola M, Martínez-Marín V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto A, Miguel M, Díaz E, Gámez A, Fresno JA, de Molina AR, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. *Oncotarget.* 2016;7(17):24217-27. Article. IF: 5.168; Q1
- * Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *New Engl J Med.* 2016;375(22):2154-64. Article. IF: 72.406; D1
- * Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma HJ, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. *Gynecol Oncol.* 2016;143(1):27-34. Article. IF: 4.959; D1
- * Pinto A, Segura PP. Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM). *Eur J Cancer Prev.* 2016;25(2):137-41. Review. IF: 2.556; Q3
- * Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Láinez N, Martínez J, Redondo A, Romero I. SEOM clinical guideline in ovarian cancer (2016). *Clin Transl Oncol.* 2016;18(12):1206-12. Article. IF: 2.353; Q3
- * Shi JJ, Zhang YF, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao ZG, Guo XY, Benitez J, Beeghly-Fadiel A, Blot W, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Bruening T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dork T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guenel P, Haiman CA, Hamann U, Hartman M, Miao H, Hollestelle A, Hopper JL, Hsiung CN, Investigators K, Ito H, Jakubowska A, Johnson N, Torres D, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Li JM, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Matsuo K, McLean C, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Borresen-Dale AL, Olson JE, Orr N, van den Ouweland AMW, Peterlongo P, Putti TC, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Hou MF, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Toland AE, Tollenaar RAEM, Tomlinson I, Truong T, Tseng CC, Wen WQ, Winqvist R, Wu AH, Yip CH, Zamora PM, Zheng Y, Floris G, Cheng CY, Hooning MJ, Martens JWM, Seynaeve C, Kristensen VN, Hall P, Pharoah PDP, Simard J, Chenevix-Trench G,

Dunning AM, Antoniou AC, Easton DF, Cai QY, Long JR. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *Int J Cancer*. 2016;139(6):1303-17. Article. IF: 6.513; Q1

- * Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, de Miguel M, Martín-Hernández R, Reglero G, Feliú J, de Molina AR. 3' UTR Polymorphism in ACSL1 gene correlates with expression levels and poor clinical outcome in colon cancer patients. *Plos One*. 2016;11():e0168423. Article. IF: 2.806; Q1
- * Vera R, Dotor E, Feliú J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM clinical guideline for the treatment of pancreatic cancer (2016). *Clin Transl Oncol*. 2016;18(12):1172-8. Article. IF: 2.353; Q3